Deal facts
- Buyer
- Cencora, Inc.
- Target
- American Oncology Network, Inc.
- Deal value
- Not disclosed
- Announced
- 21 October 2026
- Status
- Firm intention
- Sector
- Healthcare
- Country
- United States
- Consideration
- Not stated
Sources
Cencora, Inc. has entered into an Agreement and Plan of Merger with American Oncology Network, Inc. (AON), dated as of October 20, 2026. The companies announced the transaction on October 21, 2026, in a joint press release furnished as an exhibit to Cencora's Form 8-K of that date. Both companies are Delaware corporations, and Cencora's principal executive offices are in Conshohocken, Pennsylvania.
Under the agreement, Dolphins Merger Sub, Inc., a wholly-owned Cencora subsidiary, will merge with and into AON. AON will survive the merger as a wholly-owned subsidiary of Cencora.
Cencora announced the transaction together with updated fiscal year 2026 financial expectations. Its filing says the financial closing procedures for full-year 2026 were not yet complete, so actual results could differ from those expectations. Cencora said it will discuss its fiscal 2027 expectations on its fiscal fourth quarter 2026 earnings call on November 4, 2026.
The merger is subject to the conditions set out in the agreement. The filing's cautionary note warns that the deal may not close when expected or at all if required regulatory, stockholder or other approvals or other closing conditions are not received or satisfied, and that approvals could come with conditions. Among the wider risks to Cencora's results, the same note cites its de-leveraging plans and its ability to maintain its investment grade rating. No closing date is given in the filing.
Deal timeline
1 update- Firm intention
Cencora, Inc. firm intention to acquire American Oncology Network, Inc.
Item 2.02 Results of Operations and Financial Condition. On October 21, 2026, Cencora, Inc., a Delaware corporation (the “Company”), announced updated fiscal year 2026 financial expectations and the transaction described in Item 7.01 below, pursuant to the news release described in Item 7.01 below. A copy of the news release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
Source
For business owners
What would selling your own business involve?
Use the deal as a starting point, not a valuation benchmark. Learn the decisions behind a sale and apply them to your own preparation.
Guides are free to read. Free tools require email access; indicative results are not professional advice.
Explore
Browse adjacent archives
Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.
Similar deals
Similar deals
Other Healthcare M&A activity tracked by Exit Mode.
Circle Health Holdings Limited to acquire CHC Healthcare Holdings Limited
Circle Health Holdings Limited has agreed to acquire CHC Healthcare Holdings Limited in a strategic acquisition within the healthcare sector. Both entities are based in…
- Buyer
- Circle Health Holdings Limited
- Target
- CHC Healthcare Holdings Limited
- Deal value
- Not disclosed
- Deal type
- strategic acquisition
Drugs Made In America Acquisition II Corp. to acquire Alpha AI Biotech Group
Drugs Made in America Acquisition II Corp., a Cayman Islands special purpose acquisition company listed on Nasdaq, disclosed in a Form 8-K signed November 18, 2026 that…
- Buyer
- Drugs Made In America Acquisition II Corp.
- Target
- Alpha AI Biotech Group
- Deal value
- USD 600,000,000
- Deal type
- strategic acquisition
Aimei Health Technology Co., Ltd to acquire Hera Health Solutions Inc.
Aimei Health Technology Co., Ltd (Nasdaq: AFJK), a Cayman Islands blank check company, entered into a non-binding letter of intent on November 14, 2026 for a business co…
- Buyer
- Aimei Health Technology Co., Ltd
- Target
- Hera Health Solutions Inc.
- Deal value
- Not disclosed
- Deal type
- strategic acquisition
Wolfram Resources Plc to acquire Ellipses Pharma Limited
Wolfram Resources Plc (LSE: WFR), a Main Market listed special purpose acquisition company, confirmed on 16 November 2026 that it was in active discussions about a poten…
- Buyer
- Wolfram Resources Plc
- Target
- Ellipses Pharma Limited
- Deal value
- Not disclosed
- Deal type
- strategic acquisition
MaxCyte, Inc. to acquire Akron BioProducts LLC
MaxCyte, Inc., the Nasdaq-listed cell-engineering company, has agreed to acquire Akron BioProducts LLC from affiliates of Arcline Investment Management. The Securities P…
- Buyer
- MaxCyte, Inc.
- Target
- Akron BioProducts LLC
- Deal value
- USD 151,800,000
- Deal type
- strategic acquisition
Buyer history
Cencora, Inc.
See every published Exit Mode archive entry where this buyer appears.
View buyer profileMethodology
How this page is built
Layer 1 facts come from source documents, Layer 2 turns those facts into a readable narrative, and Layer 3 only appears where the editorial team flags a founder-relevant deal.
Back to the archive